Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes.

Trial Profile

Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2010

At a glance

  • Drugs Insulin aspart/insulin protamine aspart; Insulin glargine; Insulin glulisine; Insulin neutral protamine lispro/insulin lispro
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jun 2010 Results have been presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
    • 26 Jun 2010 Results reported in two abstracts at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA), according to a sanofi aventis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top